ROS1 rearrangement testing: Is immunohistochemistry changing the horizon?

ROS1 rearrangement testing: Is immunohistochemistry changing the horizon?

Bibliographic Details
Main Authors:	Anuradha Choughule, H D'Souza
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2019-01-01
Series:	Cancer Research, Statistics, and Treatment
Online Access:	http://www.crstonline.com/article.asp?issn=2590-3233;year=2019;volume=2;issue=1;spage=66;epage=68;aulast=Choughule

Similar Items

Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
by: Yoon Jin Cha, et al.
Published: (2014-01-01)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
by: Julum Nwanze, et al.
Published: (2017-09-01)

Mouse model for ROS1-rearranged lung cancer.
by: Yasuhito Arai, et al.
Published: (2013-01-01)

Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme.
by: Sun Min Lim, et al.
Published: (2015-01-01)

TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT
by: K. K. LAKTIONOV, et al.
Published: (2017-06-01)

Multiple cerebral infarctions in ROS1‐rearranged lung adenocarcinoma
by: Hiroaki Ikushima, et al.
Published: (2021-09-01)

Reviewing ROS1 immunohistochemistry vis-á-vis fluorescence in situ hybridization in NSCLC
by: Kirti G Chadha, et al.
Published: (2019-01-01)

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
by: Hayato Ogura, et al.
Published: (2017-07-01)

A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis
by: Yutaka Takahara, et al.
Published: (2020-01-01)

Clinical Significance of ROS1 Rearrangements in Non-small Cell Lung Cancer
by: Luting XU, et al.
Published: (2013-12-01)

Liquid biopsy in lung cancer-hope or hype?
by: Anuradha Choughule, et al.
Published: (2019-01-01)

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features.
by: Jianya Zhou, et al.
Published: (2016-01-01)

Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma
by: Basolo, A., et al.
Published: (2022)

ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing
by: Carleigh R. Canterbury, DDS, et al.
Published: (2021-10-01)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
by: Hiroaki Tachi, et al.
Published: (2020-07-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
by: Moushumi Suryavanshi, et al.
Published: (2017-01-01)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
by: Rossi G, et al.
Published: (2017-07-01)

Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
by: Guangdie Yang, et al.
Published: (2021-06-01)

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers
by: Noura J. Choudhury, MD, et al.
Published: (2021-07-01)

Determination of ROS1 positivity by immunohistochemistry in a multicentric cohort of 426 non-small-cell lung cancer cases in India
by: Jugnu Jain, et al.
Published: (2019-01-01)

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
by: Jongmin Lee, et al.
Published: (2019-01-01)

Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature
by: Zhu YC, et al.
Published: (2016-07-01)

Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer
by: Jiangping Yang, et al.
Published: (2021-05-01)

Immunohistochemistry
by: G Aryal
Published: (2015-09-01)

Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors
by: Wu CW, et al.
Published: (2020-10-01)

Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
by: Ling Shan, et al.
Published: (2015-01-01)

Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features
by: Cao B, et al.
Published: (2015-12-01)

Immunohistochemistry and fluorescence in-situ hybridization study for detection of anaplastic lymphoma kinase gene rearrangement in nonsmall cell lung carcinoma
by: Mohamed Hantera, et al.
Published: (2018-01-01)

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing
by: Meiying Cui, et al.
Published: (2020-11-01)

Applications of immunohistochemistry
by: Jeyapradha Duraiyan, et al.
Published: (2012-01-01)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
by: Mehta A, et al.
Published: (2020-02-01)

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
by: Peng Chen, et al.
Published: (2021-02-01)

Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report
by: Danila Comandini, et al.
Published: (2021-06-01)

TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
by: Caihua Xu, MD, et al.
Published: (2020-06-01)

Association of Helicobacter pylori in Gastric Lesions with Emphasis on Immunohistochemistry
by: Srushti Basavaraj Mulimani, et al.
Published: (2021-02-01)

Identification of PHPT1 in mouse tissues by immunohistochemistry
by: Koria, Muntaha
Published: (2007)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
by: Lan Shen, et al.
Published: (2020-05-01)

Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
by: Yi Yao, et al.
Published: (2019-02-01)

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
by: Liang Dong, et al.
Published: (2018-01-01)

Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer
by: Manish Kumar, et al.
Published: (2020-06-01)